Rivaroxaban (Xarelto)

Active ingredient: Rivaroxaban
Brand name: Xarelto

Rivaroxaban (Xarelto) is a relatively new anticoagulant medicine used to help prevent problems caused by harmful blood clots. Anticoagulants are a type of anti-clotting medicine.

Rivaroxaban can be used to:

  • prevent blood clots in people who’ve had hip or knee replacement surgery
  • prevent stroke in people with atrial fibrillation who have at least one other risk factor for stroke, such as diabetes or hypertension
  • treat and prevent deep vein thrombosis (DVT – a blood clot in a deep vein of the leg)
  • treat and prevent pulmonary embolism (PE – a blood clot in the lung).

As with other anti-clotting medicines (anticoagulant and antiplatelet medicines), there is a risk of bleeding-related side effects if you are taking rivaroxaban.

Find out more about rivaroxaban

Related information - rivaroxaban

Audience:
       

(Medicine)
12 Oct 2016 Xarelto Tablets is a brand of medicine containing the active ingredient rivaroxaban. Find out about side effects, who can take it and who shouldn’t use Xarelto Tablets by reading the latest Australian consumer medicine information, plus tips on how to use medicines wisely and safely.
(Medicine)
09 Dec 2014 Fish oil is generally well tolerated, with few side effects. However, it can interfere with blood clotting at high doses.
(Consumer publication)
11 Aug 2014 Stopping dabigatran suddenly is dangerous, and could put you at risk of blood clots, leading to a stroke. Talk to your doctor about the risks and benefits in your particular situation before making any decision about stopping dabigatran.
(Media release)
06 Aug 2014 With anticoagulant medicine dabigatran (brand name Pradaxa) in the news this week following reports that safety information about the medicine had been withheld by the manufacturer, NPS MedicineWise is reminding people not to stop taking it without talking to their doctor.
For health professionals (Medicine)
08 May 2014 The vitamin K antagonist warfarin and the newer oral anticoagulants dabigatran and rivaroxaban are approved treatments for stroke prevention in people with non-valvular atrial fibrillation (AF), but dabigatran and rivaroxaban are not PBS listed for this indication. Read about which people with non-valvular AF need anticoagulation and the role of these different medicines.
For health professionals (Health professional publication)
13 Mar 2014 The vitamin K antagonist warfarin can be used for the prevention and treatment of venous thromboembolism (VTE). The newer oral anticoagulants dabigatran, rivaroxaban and apixaban are all PBS subsidised for the prevention of VTE in patients undergoing total hip replacement or total knee replacement. Rivaroxaban is also PBS subsidised for treatment of acute symptomatic deep vein thrombosis without symptomatic pulmonary embolism and prevention of recurrent VTE. Read about the place in therapy of these medicines.
(Media release)
01 Sep 2013 NPS MedicineWise is reiterating safety messages around the newer anticoagulants dabigatran (Pradaxa) and apixaban (Eliquis) following their PBS listing for preventing stroke on 1 September 2013 – and again for rivaxabaran (Xarelto) which was PBS listed in August for the same purpose.
(Media release)
01 Sep 2013 NPS MedicineWise is reiterating safety messages around the newer anticoagulant medicines dabigatran (brand name Pradaxa) and apixaban (Eliquis) with their PBS listing for preventing stroke on 1 September 2013. The safety messages also apply for rivaroxaban (Xarelto) which was PBS-listed last month.
(Media release)
01 Aug 2013 The 10th anniversary edition of NPS RADAR contains reviews for new medicines listed on the Pharmaceutical Benefits Scheme (PBS) including rivaroxaban (Xarelto), rotigotine patches (Neupro) and mifepristone (Mifepristone Linepharma) followed by misoprostol (GyMiso).
For health professionals (Health professional publication)
01 Aug 2013 Rivaroxaban (Xarelto) is PBS listed as an alternative to parenteral anticoagulation with heparin and dose-adjusted warfarin for treatment of DVT and prevention of VTE recurrence.